Current treatment options in patients with mastocytosis: Status in 2015 and future perspectives

European Journal of Haematology

Volumn 94, Issue 6, 2015, Pages 474-490

  Arock, Michel ^a,b   Akin, Cem ^c   Hermine, Olivier ^d,e   Valent, Peter ^f  

^a Ecole Normale Superieure de Cachan   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UMR S 1168   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allogeneic stem cell transplantation; Antihistamines; Cytoreduction; KIT mutations; Mastocytosis; Surface antigens; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ADRENALIN; ALPHA INTERFERON; ANTIGEN; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLADRIBINE; DASATINIB; GLUCOCORTICOID; IMATINIB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MASITINIB; MEMBRANE ANTIGEN; MIDOSTAURIN; OMALIZUMAB; ANTINEOPLASTIC AGENT; AUTACOID; CYTOKINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALTERNATIVE MEDICINE; APOPTOSIS; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LIFE EXPECTANCY; MAST CELL; MAST CELL DEGRANULATION; MAST CELL LEUKEMIA; MEDIATOR RELEASE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; ALLOTRANSPLANTATION; DISEASE MANAGEMENT; IMMUNOLOGY; IMMUNOTHERAPY; MASTOCYTOSIS; METABOLISM; PATHOLOGY; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CYTOKINES; DISEASE MANAGEMENT; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; MAST CELLS; MASTOCYTOSIS; MOLECULAR TARGETED THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84929129792     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12544     Document Type: Review

References (135)

1. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999;94:2333-42.
2. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2006;315:13-34.
3. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today 1994;15:111-4.
4. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010;3:497-516.
5. Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013;13:693-701.
6. Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 2012;5:261-74.
7. Lee JK, Whittaker SJ, Enns RA, Zetler P. Gastrointestinal manifestations of systemic mastocytosis. World J Gastroenterol 2008;14:7005-8.
8. Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013;3:159-72.
9. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88:612-24.
10. Stoecker MM, Wang E. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. Arch Pathol Lab Med 2012;136:832-8.
11. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010;116:5812-7.
12. George TI, Horny HP. Systemic mastocytosis. Hematol Oncol Clin North Am 2011;25:1067-83, vii.
13. Sokol H, Georgin-Lavialle S, Canioni D, et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol 2013;132:866-73 e1-3.
14. Rossini M, Zanotti R, Viapiana O, et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 2014;34:383-96.
15. Valent P, Sotlar K, Sperr WR, et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014;25:1691-700.
16. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.
17. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
18. Valent P, Horny H-P, Li CY. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours. Lyon, France: IARC Press ed; 2001; 291-302.
19. Horny HP AC, Metcalfe DD, Escribano L, Bennett JM, Valent P, Bain BJ. Mastocytosis (mast cell disease). In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours. Lyon, France: IARC Press edn: 2008. 54-63.
20. Valent P. Systemic mastocytosis. Cancer Treat Res 2008;142:399-419.
21. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am 2014;34:207-18.
22. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, Bennett JM, Metcalfe DD. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635-41.
23. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am 2014;34:239-62.
24. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-15.
25. Yang Y, Letard S, Borge L, et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010;116:1114-23.
26. Lasota J. Not all c-kit mutations can be corrected by imatinib. Lab Invest 2007;87:317.
27. Gotlib J, Kluin-Nelemans HC, George TI, et al. Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial. Blood 2014;124:636.
28. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5.
29. Alvarez-Twose I, Gonzalez P, Morgado JM, Jara-Acevedo M, Sanchez-Munoz L, Matito A, Mollejo M, Orfao A, Escribano L. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012;30:e126-9.
30. Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013;122:2460-6.
31. Briley LD, Phillips CM. Cutaneous mastocytosis: a review focusing on the pediatric population. Clin Pediatr (Phila) 2008;47:757-61.
32. Siebenhaar F, Akin C, Bindslev-Jensen C, Maurer M, Broesby-Olsen S. Treatment strategies in mastocytosis. Immunol Allergy Clin North Am 2014;34:433-47.
33. Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112:946-56.
34. Olafsson JH. Cutaneous and systemic mastocytosis in adults. A clinical, histopathological and immunological evaluation in relation to histamine metabolism. Acta Derm Venereol Suppl (Stockh) 1985;115:1-43.
35. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol 2007;95:167-255.
36. Sillaber C, Baghestanian M, Bevec D, et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999;162:1032-41.
37. Valent P, Baghestanian M, Bankl HC, Sillaber C, Sperr WR, Wojta J, Binder BR, Lechner K. New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. Thromb Haemost 2002;87:786-90.
38. Schwartz LB. Mediators of human mast cells and human mast cell subsets. Ann Allergy 1987;58:226-35.
39. Macpherson JL, Kemp A, Rogers M, Mallet AI, Toia RF, Spur B, Earl JW, Chesterman CN, Krilis SA. Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 1989;77:391-6.
40. Saito M, Fujimura M, Ogawa H, Matsuda T. Role of leukotrienes and platelet activating factor in allergic bronchoconstriction and their interactions in guinea pig airway in vivo. Prostaglandins Leukot Essent Fatty Acids 1993;49:579-85.
41. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006;26:465-85.
42. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008;49:7-19.
43. Niyonsaba F, Ushio H, Hara M, et al. Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 2010;184:3526-34.
44. Hartmann K, Wagner N, Rabenhorst A, Pflanz L, Leja S, Forster A, Gehring M, Kapp A, Raap U. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol 2013;132:232-5.
45. Rabenhorst A, Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep 2014;14:423.
46. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012;157:215-25.
47. Konrad FM, Schroeder TH. Anaesthesia in patients with mastocytosis. Acta Anaesthesiol Scand 2009;53:270-1.
48. Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol 1989;83:866-70.
49. Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006;5:61-77.
50. Worobec AS, Metcalfe DD. Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 2002;127:153-5.
51. Lytinas M, Kempuraj D, Huang M, et al. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 2002;23:45-51.
52. Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Mirkina I, Willmann M, Valent P. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol 2010;38:896-907.
53. Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012;29:222-3.
54. Mullol J, Bousquet J, Bachert C, Canonica GW, Gimenez-Arnau A, Kowalski ML, Simons FE, Maurer M, Ryan D, Scadding G. Update on rupatadine in the management of allergic disorders. Allergy 2015;70(Suppl. 100):1-24.
55. Gorska A, Niedoszytko M, Lange M, Chelminska M, Nedoszytko B, Wasag B, Slominski JM, Gruchala-Niedoszytko M, Nowicki R, Jassem E. The risk factors of anaphylaxis in patients with mastocytosis. Pol Arch Med Wewn 2015;125:46-53.
56. Rueff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006;6:284-8.
57. Simons FE. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol 2009;124:625-36, quiz 37-8.
58. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519-26.
59. Oppong E, Flink N, Cato AC. Molecular mechanisms of glucocorticoid action in mast cells. Mol Cell Endocrinol 2013;380:119-26.
60. Ellingsen AR, Thestrup-Pedersen K. Treatment of chronic idiopathic urticaria with topical steroids. An open trial. Acta Derm Venereol 1996;76:43-4.
61. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249-57.
62. Taylor AM, Galli SJ, Coleman JW. Dexamethasone or cyclosporin A inhibits stem cell factor-dependent secretory responses of rat peritoneal mast cells in vitro. Immunopharmacology 1996;34:63-70.
63. Inoue T, Katoh N, Kishimoto S. Prolonged topical application of tacrolimus inhibits immediate hypersensitivity reactions by reducing degranulation of mast cells. Acta Derm Venereol 2006;86:13-6.
64. Correia O, Duarte AF, Quirino P, Azevedo R, Delgado L. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J 2010;16:8.
65. Ozdemir D, Dagdelen S, Erbas T, Agbaht K, Serefhanoglu S, Aksu S, Ersoy-Evans S. Hypotension, syncope, and fever in systemic mastocytosis without skin infiltration and rapid response to corticosteroid and cyclosporin: a case report. Case Rep Med 2010;2010:782595.
66. Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician 2010;81:1440-6.
67. Netzer NC, Kupper T, Voss HW, Eliasson AH. The actual role of sodium cromoglycate in the treatment of asthma-a critical review. Sleep Breath 2012;16:1027-32.
68. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;85:852-5.
69. Edwards AM, Capkova S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep 2011;2011:bcr0220113910.
70. Lester MR, Bratton DL. Adverse reactions to cromolyn sodium: patient report and review of the literature. Clin Pediatr (Phila) 1997;36:707-10.
71. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008;147:338-43.
72. Crawhall JC, Wilkinson RD. Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition. Clin Invest Med 1987;10:1-4.
73. Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract 2014;2:266-70.
74. Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69:1838-41.
75. Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011;124:776-8.
76. Laroche M, Bret J, Brouchet A, Mazieres B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 2007;26:242-3.
77. Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol 2015;11:461-70.
78. Ali AS, Lax AS, Liljestrom M, Paakkari I, Ashammakhi N, Kovanen PT, Konttinen YT. Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin Chem Lab Med 2006;44:672-4.
79. Schleyer V, Meyer S, Landthaler M, Szeimies RM. ["Smoldering systemic mastocytosis. "Successful therapy with cladribine]. Hautarzt 2004;55:658-62.
80. Valent P, Blatt K, Eisenwort G, et al. FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. Leuk Res Rep 2014;3:8-13.
81. Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014;32:3264-74.
82. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-23.
83. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790-4.
84. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-7.
85. Bjerrum OW. Interferon-alpha treatment in systemic mastocytosis. Curr Drug Targets 2011;12:433-6.
86. Bohm A, Sonneck K, Gleixner KV, et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 2010;38:744-55.
87. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001;344:307-9.
88. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-6.
89. Hermine O, Hirsh I, Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients. Blood 2010;116:1982.
90. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004;104:1931-9.
91. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-92.
92. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-25.
93. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007;87:365-71.
94. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NC, Cavenagh JD. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8.
95. Hoffmann KM, Moser A, Lohse P, Winkler A, Binder B, Sovinz P, Lackner H, Schwinger W, Benesch M, Urban C. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 2008;112:1655-7.
96. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-9.
97. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009;4:e7258.
98. Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010;85:921-5.
99. Georgin-Lavialle S, Lhermitte L, Suarez F, et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 2012;89:47-52.
100. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol 2007;18(Suppl. 6):vi42-6.
101. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.
102. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286-91.
103. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007;92:1451-9.
104. Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica 2013;98:1450-7.
105. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-15.
106. Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B, Cannell P. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 2008;80:456-8.
107. Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res 2014;201:27-65.
108. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
109. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009;39:1711-20.
110. Chandesris M-O, Damaj G, Canioni D, et al. Treatment of advanced systemic mastocytosis with PKC412: the French compassionate use programme experience and historical comparison. Blood 2014;124:3193.
111. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011;118:1885-98.
112. Gleixner KV, Mayerhofer M, Hormann G, Schuch K, Cerny-Reiterer S, Peter B, Herrmann H, Pickl WF, Sillaber C, Valent P. Bosutinib blocks Lyn and Btk activation and synergizes with the KIT D816V-targeting drug midostaurin in inducing apoptosis in neoplastic human mast cells. ASH Annu Meet Abstr 2009;114:1717.
113. Ai J, Tiu RV. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations. Ther Adv Hematol 2014;5:107-20.
114. Jin B, Ding K, Pan J. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing beta-catenin signaling. Mol Cancer Ther 2014;13:1217-30.
115. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007;109:315-22.
116. Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007;26:3904-8.
117. Jin Y, Ding K, Wang D, Shen M, Pan J. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Cancer Lett 2014;353:115-23.
118. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Shimabukuro-Vornhagen A, Skoetz N, Scheid C, von Bergwelt-Baildon M. Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults-a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015 (in press).
119. Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006;37:353-8.
120. Valent P, Cerny-Reiterer S, Herrmann H, Mirkina I, George TI, Sotlar K, Sperr WR, Horny HP. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010;23:369-78.
121. Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008;112:2463-73.
122. Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009;147:495-506.
123. Saleh R, Wedeh G, Herrmann H, et al. A new human mast cell line expressing a functional IgE receptor converts to factor-independence and tumorigenicity by KIT D816V-transfection. Blood 2014;124:111-20.
124. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007;110:2593-9.
125. Smrz D, Kim MS, Zhang S, et al. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 2011;118:6803-13.
126. Aichberger KJ, Gleixner KV, Mirkina I, et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009;114:5342-51.
127. Peter B, Cerny-Reiterer S, Hadzijusufovic E, et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol 2014;95:95-104.
128. Teodosio C, Mayado A, Sanchez-Munoz L, et al. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol 2015;97:49-59.
129. Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-25.
130. Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011;52:740-4.
131. Hoermann G, Blatt K, Greiner G, et al. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J 2014;28:3540-51.
132. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, Hessel H, Berezowska S, Mullauer L, Valent P, Horny HP. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011;24:585-95.
133. van Anrooij B, Kluin PM, Oude Elberink JN, Kluin-Nelemans JC. CD30 in systemic mastocytosis. Immunol Allergy Clin North Am 2014;34:341-55.
134. - stem cells in various myeloid malignancies. Leuk Lymphoma 2006;47:207-22.
135. Krauth MT, Bohm A, Agis H, Sonneck K, Samorapoompichit P, Florian S, Sotlar K, Valent P. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol 2007;35:108-16.